Scientific paper| Volume 157, ISSUE 6, P548-551, June 1989

Download started.


Additive effect of an immunomodulator and broad-spectrum antibiotic in fecal peritonitis

      This paper is only available as a PDF. To read, Please Download here.


      We examined the effect of muramyl dipeptide (3 μg/g body weight) and a broad-spectrum antibiotic cefoxitin (15 mg/kg) on survival and systemic bacteremia in rats with peritonitis. When muramyl dipeptide given 24 hours prior to placement of the bacterial inoculum was combined with a single prophylactic dose of cefoxitin, survival was 100 percent (p < 0.001) and systemic bacteremia at 4 hours postinoculation was significantly decreased. Twenty-four hour pretreatment with either muramyl dipeptide alone or cefoxitin alone was associated with survival rates of 43 percent and 56 percent, respectively.
      When muramyl dipeptide was given with cefoxitin at the time of administration of the bacterial inoculum, no survival advantage was seen over the use of cefoxitin alone. There were no significant differences among groups in quantitative bacteremia at 24 hours postinoculation or in the number of intraabdominal abscesses. This study clearly demonstrates an additive effect of muramyl dipeptide pretreatment given with a prophylactic dose of cefoxitin in a human fecal peritonitis rat model.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ellouz T
        • Adam A
        • Ciorbaru R
        • Lederer E
        Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.
        Biochem Biophys Res Commun. 1974; 59: 1317-1325
        • Fevrier M
        • Birrien JL
        • LeClerc C
        • Chedid L
        • Liacopoulos P
        The macrophage, target cell of the synthetic adjuvant muramyl dipeptide.
        Eur J Immunol. 1979; 8: 558-562
        • Chedid L
        • Parant M
        • Parant F
        Enhancement of nonspecific immunity to Klebsiella pneumonia infection by synthetic immunoadjuvant (N-acetyl-muramyl-L-alanyl-D-isoglutamine) and several analogs.
        Immunology. 1977; 74: 2089-2093
        • Chedid L
        • Audibert F
        • LeFrancier P
        Modulation of the immune response by a synthetic adjuvant and analogs.
        in: 3rd ed. Proc Natl Acad Sci USA. 73. 1976: 7472-7475
        • Polk Jr, HC
        • Galland RB
        Enhancement of nonspecific host defense mechanisms.
        in: Polk Jr, HC Infection and the surgical patient. Churchill Livingstone, New York1982: 101-109
        • Galland RB
        • Heine KJ
        • Polk Jr, HC
        Nonspecific stimulation of host defenses against bacterial challenge in immunosuppressed mice.
        Arch Surg. 1983; 118: 333-337
        • Brown GL
        • Foshee H
        • Pietsch J
        • Polk Jr, HC
        Muramyl dipeptide enhances survival from experimental peritonitis.
        Arch Surg. 1986; 121: 47-49
        • Polk Jr, HC
        • Galland RB
        • Ausobsky JR
        Nonspecific enhancement of resistance to bacterial infection.
        Ann Surg. 1982; 196: 436
        • Nichols RL
        • Smith JW
        • Balthazar ER
        Peritonitis and intraabdominal abscess.
        J Surg Res. 1978; 25: 129-134
        • McCoy DM
        • Brown GL
        • Ausobsky JR
        • Polk Jr, HC
        Muramyl dipeptide enhances in vitro peritoneal macrophage phagocytic activity.
        Am Surg. 1985; 51: 634-636
        • Pabst MJ
        • Johnston Jr, RB
        Increased production of superoxide anion by macrophage exposed in vivo to muramyl dipeptide or lipopolysaccharide.
        J Exp Med. 1980; 151: 101
        • Tanaka A
        • Nagao S
        • Nagao R
        • Kotani S
        • Shiba T
        • Kusumoto S
        Stimulation of the reticuloendothelial system by muramyl dipeptide.
        Infect Immun. 1979; 24: 302-307
        • Cheadle WG
        • Hershman MJ
        • Pietsch JD
        • Polk Jr, HC
        The natural history of murine intraabdominal abscess formation.
        Arch Surg. 1988; 123: 1342-1346
        • Fraser-Smith EB
        • Matthews TR
        Protective effect of muramyl dipeptide analogs against infection of Pseudomonas aeruginosa or Candida albicans in mice.
        Infect Immun. 1981; 34: 67-83
        • Friedman H
        • Warren G
        Muramyl dipeptide-induced enhancement of phagocytosis of antibiotic pretreated Escherichia coli by macrophages.
        in: 3rd ed. Proc Soc Exp Biol Med. 176. 1984: 366-370
        • Almdahl SM
        • Bogwald J
        • Hoffman J
        • Giercksky KE
        • Seljelid R
        Protection by aminated glucan in experimental endogenous peritonitis.
        Eur Surg Res. 1987; 19: 79-85
        • Browder W
        • Williams D
        • Sherwood E
        • McNamee R
        • Jones E
        • DiLuzio N
        Synergistic effect of nonspecific immunostimulation and antibiotics in experimental peritonitis.
        Surgery. 1987; 102: 206